Expression of cysteine-rich secretory protein 2 in patients with asthenozoospermia and its clinical significance.
- Author:
Junhao ZHOU
1
;
Kangyi XUE
;
Mingkun CHEN
;
Qizhao ZHOU
;
Jiankun YANG
;
Jun BIAN
;
Xin LI
;
Wenbin GUO
;
Hui XIA
;
Tao QI
;
Cundong LIU
Author Information
- Publication Type:Journal Article
- MeSH: Asthenozoospermia; metabolism; Case-Control Studies; Fertility; Follow-Up Studies; Glycoproteins; metabolism; Humans; Male; RNA, Messenger; Sperm Motility; Spermatozoa; metabolism
- From: Journal of Southern Medical University 2014;34(10):1528-1533
- CountryChina
- Language:Chinese
-
Abstract:
OBJEVTIVETo investigate the expression of cysteine-rich secretory protein 2 (CRISP2) in spermatozoa of patients with asthenozoospermia and explore its clinical significance.
METHOSSemen samples were collected from 24 normal volunteers and 24 patients with asthenozoospermia for detecting CRISP2 mRNA and protein expressions using qRT-PCR and Western blotting, respectively. The correlation of CRISP2 expressions with sperm morphology, progressive motility and fertility prognosis were analyzed in patients with asthenozoospermia.
RESULTSCRISP2 protein expression was obviously lowered in the ejaculated spermatozoa of patients with asthenozoospermia as compared to the normal volunteers, but no significant difference in CRISP2 mRNA expression was found between the two groups. Correlation analysis showed that CRISP2 protein expression was positively correlated with normal sperm morphology (r=0.6182, P=0.0037) and progressive motility (r=0.6309, P=0.0029). Follow-up study of the patients revealed a higher fertility rate in patients with a relatively high CRISP2 protein expression than in those with low CRISP2 protein expression (80.0% vs 20.0%, P=0.0230).
CONCLUSIONThe expression level of CRISP2 protein is positively correlated with normal sperm morphology and progressive motility. A reduced CRISP2 protein expression indicates poor fertility prognosis of patients with asthenozoospermia, suggesting the potential value of CRISP2 as a novel therapeutic target for treating asthenozoospermia.